Study on UB-VV400 and Rapamycin for Treating Difficult B-cell Blood Cancers
Sponsor: Umoja Biopharma
Sponsor score: 0
ClinicalTrials ID:NCT07735533
This clinical trial is testing a new treatment using UB-VV400 and Rapamycin to see if it is safe and effective for patients with B-cell blood cancers that have returned or not responded to previous treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to find the best dose and evaluate the safety and effectiveness of a new treatment, UB-VV400, in combination with Rapamycin for patients with B-cell blood cancers, such as large B-cell lymphoma, that have come back or are not responding to treatment.
Eligibility Criteria
Inclusion Criteria
- Must be 18 years or older.
- Must agree to participate and provide written consent.
- Have large B-cell lymphoma that has returned or not responded to treatment.
- Have cancer that can be measured using specific medical criteria.
- Cancer cells must show CD22 markers.
- Must not have serious other diseases or uncontrolled infections.
- Must be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Must have adequate organ function.
Exclusion Criteria
- Women who are pregnant or breastfeeding cannot participate.
- Cannot have cancer that is only in the central nervous system (CNS).
- Cannot have had a previous bone marrow transplant from a donor, gene therapy, or certain types of cell transfers, except for specific exceptions like CAR T cells.
- Cannot have a history of or active HIV.
- Cannot have active or chronic hepatitis B or active hepatitis C.
- Cannot have systemic immune system diseases, except for well-controlled Type I diabetes or thyroid disease.
- Cannot have ongoing CNS disease that affects neurological assessment.
- Cannot have uncontrolled chest pain or other serious heart conditions.
- Cannot be participating in another clinical trial with interventions.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Sarah Cannon Research Institute | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.
